GEFITINIB

GEFITINIB

Application

Gefitinib has been used : To study its effective use in endometrial cancer therapy Cell proliferation, cell cycle and apoptosis assays Cell viability assay and colony formation assay

Biochem/physiol Actions

Gefitinib is a selective epidermal growth factor receptor tyrosine kinase (EGFR TK) inhibitor. Gefitinib has antineoplastic activity, and has been approved for the treatment on non-small cell lung cancer (NSCLC).Gefitinib has a higher affinity for ATP (adenosine triphosphate) binding site in the EGFR tyrosine kinase domain than ATP. Hence, gefitinib is known to inhibit the progression of endometrial cancer.

Packaging

10, 50 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575227 GEFITINIB white to beige 100 XGALLCVXEZPNRQ-UHFFFAOYSA-N 1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) SIGMA-ALDRICH room temp DMSO: 10 mg/mL, clear powder ≥98% (HPLC)
£140.68 (exc VAT) per 10MG
-
+
3575228 GEFITINIB white to beige 100 XGALLCVXEZPNRQ-UHFFFAOYSA-N 1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) SIGMA-ALDRICH room temp DMSO: 10 mg/mL, clear powder ≥98% (HPLC)
£571.07 (exc VAT) per 50MG
-
+